• {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}
      • logo ubrevly
      Product Monograph
      PATIENT INFORMATION
      Important Safety Information

      UBRELVY is indicated for the acute treatment of migraine, with or without aura, in adults.

      when migraine strikes
      when migraine strikes
      when migraine strikes

      A first-in-class small-molecule CGRP receptor antagonist.*

      SAFETY INFORMATION

      Click here for additional safety information and for a link to the Product Monograph discussing:

      ●Contraindications with concomitant use of strong CYP3A4 inhibitors.

      ●Relevant warnings and precautions regarding driving and operating machinery, hypersensitivity reactions, may reduce effectiveness of oral contraceptives, use in pregnant or breast-feeding women and dose selection in geriatric patients.

      ●Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

       

      FOR MORE INFORMATION

      For any questions related to UBRELVY, you can contact AbbVie Medical Information at 1-844-241-5011. 

      SAFETY INFORMATION

      Click here for additional safety information and for a link to the Product Monograph discussing:

      ●Contraindications with concomitant use of strong CYP3A4 inhibitors.

      ●Relevant warnings and precautions regarding driving and operating machinery, hypersensitivity reactions, may reduce effectiveness of oral contraceptives, use in pregnant or breast-feeding women and dose selection in geriatric patients.

      ●Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

       

      FOR MORE INFORMATION

      For any questions related to UBRELVY, you can contact AbbVie Medical Information at 1-844-241-5011. 

      SAFETY INFORMATION

      Click here for additional safety information and for a link to the Product Monograph discussing:

      ●Contraindications with concomitant use of strong CYP3A4 inhibitors.

      ●Relevant warnings and precautions regarding driving and operating machinery, hypersensitivity reactions, may reduce effectiveness of oral contraceptives, use in pregnant or breast-feeding women and dose selection in geriatric patients.

      ●Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

       

      FOR MORE INFORMATION

      For any questions related to UBRELVY, you can contact AbbVie Medical Information at
      1-844-241-5011. 

      CGRP=calcitonin gene-related peptide. 

      * Comparative clinical significance unknown. 

      References:

      1. UBRELVY (ubrogepant) Product Monograph. AbbVie Corporation. 

      2. Data on File, AbbVie Corporation. 

      3. “Summary Basis of Decision – Ubrelvy”. Health Canada. Updated March 30, 2023. https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD00631 (accessed April 19, 2023). 

      UBRELVY and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation. 

      © 2024 AbbVie. All rights reserved. 

      CA-UBR-230004A / JN24  

      UBRELVY and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation. 

      © 2024 AbbVie. All rights reserved. 

      CA-UBR-230004A / JN24  

      This website is intended for Canadian Healthcare Professionals

      Copyright® 2022 AbbVie Corporation. Canada. 

      Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.